ABCB1 and cancer: Identified PI3K 110α/β as novel MDR-related enzyme units and developed PBDF nanoparticles to inhibit PI3K-mediated MDR in cancer cells. PBDF nanoparticles synergistically target PI3K 110α/β to suppress ABCB1 expression and enhance anti-MDR efficacy